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Edited by Veli-Pekka LehtoAbstract Hypoxia elicits a wide range of responses that occur
at diﬀerent organizational levels in the body. Hypoxia is not only
a signal for energy conservation and metabolic change, but
triggers expression of a select set of genes. The transcription
factor hypoxia-inducible factor 1 (HIF-1) is now appreciated to
be a master factor of the gene induction. Although knowledge on
molecular mechanisms of HIF-1 activation in response to
hypoxia is accumulating, the molecular mechanism of mainte-
nance of HIF-1 activity under normoxic conditions remains to be
elucidated. We demonstrate that the intravenous anesthetic
propofol reversibly inhibits HIF-1 activity and the gene expres-
sion mediated by HIF-1 by blocking the synthesis of the HIF-1a
subunit under 20% or 5% O2 conditions, but not under 1% O2
conditions.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adaptation to hypoxia and maintenance of O2 homeostasis
involve a wide range of cellular and systemic responses that
occur at diﬀerent organizational levels in the body [1]. Hypoxia
induces expression of a select set of genes encoding glycolytic
enzymes and glucose transporters that generate ATP under
anaerobic conditions [2,3]. The transcription factor hypoxia-
inducible factor 1 (HIF-1) plays an essential role in the
maintenance of O2 homeostasis [3]. HIF-1 is a heterodimer,
consisting of HIF-1a and HIF-1b subunits, which bind to
speciﬁc regulatory sequences known as hypoxia response ele-
ments (HREs). The biological activity is determined by the
expression and activity of the HIF-1a subunit [4]. HIF-1a
protein expression level is determined by the balance between
protein synthesis and degradation. The mechanisms regulating
HIF-1a protein expression and transcriptional activity have
been most extensively analyzed. The von Hippel–Lindau tu-* Corresponding author.
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doi:10.1016/j.febslet.2004.10.042mor-suppressor protein (VHL) has been identiﬁed as the HIF-
1a-binding component of a ubiquitin-protein ligase that tar-
gets HIF-1a for proteasomal degradation in non-hypoxic cells.
Under hypoxic conditions, the hydroxylation of speciﬁc pro-
line and asparagine residues in HIF-1a is inhibited due to
substrate (O2) limitation, resulting in HIF-1a protein stabil-
ization and transcriptional activation [5]. The iron chelator
desferrioxamine (DFX) inhibits the prolyl (prolyl hydroxylase
domain containing protein [PHD] 1–3) and asparaginyl (factor
inhibiting HIF-1 [FIH-1]) hydroxylases, which contain Fe2þ at
their catalytic sites, causing HIF-1a stabilization and trans-
activation under normoxic conditions [5]. On the other hand,
we have reported that certain growth factors such as IGF-1 [6],
prostaglandin E2 [7], and the nitric oxide donor NOC18 [8]
increase the rate of HIF-1a protein synthesis rather than in-
creasing the stability of HIF-1. Activated HIF-1 induces ex-
pression of its target genes, which play key roles in glycolytic
energy metabolism, erythropoiesis and angiogenesis even un-
der non-hypoxic conditions as well as hypoxic conditions [9].
However, few study have investigated the inhibitory regulation
of HIF-1 activity under non-hypoxic conditions.
We previously reported that the volatile anesthetic halo-
thane strongly inhibits the hypoxia-induced HIF-1 activation
in the established cell line Hep3B [10]. In this study we focus
on the intravenous anesthetic propofol. So far there has been
no report about the eﬀect of propofol on the hypoxia-induced
gene responses mediated by HIF-1. In this study we demon-
strate that propofol inhibits HIF-1 activity by suppressing
HIF-1a protein synthesis and that the inhibition is dependent
on the cellular oxygen tension.2. Materials and methods
2.1. Cell culture and reagents
Hep3B cells were maintained in minimum essential medium (MEM)
with Earle’s salts supplemented with 10% fetal bovine serum (FBS),
essential amino acids, pyruvate, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin [8,11]. HEK293 cells was maintained in Dulbecco’s
MEM medium supplemented with 10% FBS, 100 U/ml penicillin, and
0.1 mg/ml streptomycin [8,11]. Human umbilical vein endothelial cells
(HUVECs) were obtained from Kurabo (Osaka, Japan). The intra-
venous anesthetic 2,6-Diisopropylphenol (Propofol) and its inactive
analogue 2,4-Diisopropylphenol as an anesthetic, DMSO as solvent,blished by Elsevier B.V. All rights reserved.
Fig. 1. Propofol inhibits HIF-1 activity in Hep3B cells. Hep3B cells
were exposed to 20% or 1% O2 with or without 100 lM propofol for
4 h and harvested for immunoblot assays using anti-HIF-1a and -HIF-
1b Abs (A). Studies on dose-dependency (B) and time-course (C) were
performed in indicated conditions. In (D), Hep3B cells were exposed to
20%, 5%, or 1% O2 with or without 100 lM propofol.
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Sigma (St. Louis, MO). The inhibitor of protein synthesis cyclohexi-
mide (CHX) and the cell-permeable proteasome inhibitor MG132 were
from Calbiochem (San Diego, CA). The antioxidants N-acetyl-cysteine
(NAC) and dithiothreitol (DTT) were from Calbiochem (San Diego,
CA). Ascorbate and a-tocopherol were from Sigma (St. Louis, MO).
2.2. Plasmid constructs
Reporter plasmid p2.1, which contains a 68-bp HRE from the hu-
man enolase 1 (ENO1) gene, an SV40 promoter, and luciferase coding
sequences, was described previously [8,11,12]. The Renilla luciferase
expression plasmid pRL-SV40 was from Promega (Madison, WI).
2.3. Hypoxic treatment
Cells were maintained in a multi-gas incubator (APMW-36, Astec,
Japan) and were exposed to hypoxia (1% O2–5% CO2–94% N2 or 5%
O2–5% CO2–90% N2) at 37 C [8,11].
2.4. Immunoblot assays
Whole cell lysates were prepared using ice-cold lysis buﬀer (0.1%
SDS, 1% NP-40, 5 mM EDTA, 150 mM NaCl, 50 mM Tris-Cl (pH
8.0), 2 mM DTT, 1 mM sodium orthovanadate, and complete protease
inhibitor [Roche Applied Science, Tokyo Japan]) following a protocol
described previously [8,11]. 100-lg aliquots were fractionated by 7.5%
SDS–PAGE and subjected to immunoblot assay using mouse mono-
clonal antibody against HIF-1a (BD Biosciences, San Jose, CA) or
HIF-1b (H1b234; Novus Biologicals, Littleton, CO) at 1:1000 dilution
and HRP-conjugated mouse monoclonal antibodies for mouse IgG
(Amersham Bioscience, Piscataway, NJ, 1:1000 dilution). Anti-ERK3
antibody was from SantaCruz and used at 1:1000 dilution (San Diego,
CA). Chemiluminescent signal was developed using ECL reagent
(Amersham Biosciences).
2.5. RT-PCR
The RT-PCR protocol is described elsewhere [8]. Cells were har-
vested, and RNA was isolated with TRIzol (Invitrogen). 1 lg of total
RNA was subjected to ﬁrst strand cDNA synthesis using random
hexamers (SuperScript II RT kit, Invitrogen). cDNAs were ampliﬁed
with TaqGold polymerase (Roche, Manheim, Germany) in a thermal
cycler with the speciﬁc primers (sequences of the primers can be pro-
vided by request). For each primer pair, PCR was optimized for cycle
number to obtain linearity between the amount of input RT product
and output PCR product. Thermocycling conditions were 30 s at 94
C, 60 s at 57 C, and 30 s at 72 C for 20 (lactate dehydrogenase
[LDHA]), 25 (vascular endothelial growth factor [VEGF]), 30 (PHD-
1), 30 (PHD-2), 30 (PHD-3), 30 (FIH-1), 25 (HIF-1a), and 20 (18S
rRNA) cycles preceded by 10 min at 94 C. PCR products were frac-
tionated by 1.5% SeaKem GTG Agarose gel electrophoresis, stained
with ethidium bromide, and visualized with UV. Quantiﬁcation of
ampliﬁed mRNA was done by densitometry assisted by the image
analysis software NIH Image (version 1.62).
2.6. Reporter gene assay
Reporter assays were performed in Hep3B cells [8,11]. 5 104 cells
were plated per well and incubated for an overnight, and were subse-
quently transfected 200 ng of reporter gene plasmid p2.1 and 50 ng of
pRL-SV40 pre-mixed with Fugene 6 transfection reagent (Roche).
Cells were treated with the reagents in 6 h, and incubated with or
without propofol under normoxic or hypoxic conditions for another 18
h. The cells were harvested and the luciferase activity of each well was
measured in the same dosage of cell lysate with the use of Dual-Lu-
ciferase Reporter Assay System (Promega). For each experiment, at
least two independent transfections were performed in triplicate and
representative data are shown.
2.7. In vitro HIF-1a-VHL interaction assay
Glutathione S-transferase (GST)-HIF-1a (429–608) fusion protein
was expressed in Escherichia coli as described. Biotinylated methio-
nine-labeled proteins were generated in reticulocyte lysates using the
TNT T7 coupled transcription/translation system and Transcend
Biotinylated tRNA (Promega). 25-lg aliquots of HEK293 cell lysate
were preincubated with propofol or DFX for 30 min at 30 C, 5 lg of
GST-HIF-1a (429–608) was added and incubated for 30 min at 30 C.
A 5-ll aliquot of in vitro-translated biotinylated VHL protein was
mixed with 5 lg of GST fusion protein in a ﬁnal volume of 200 ll ofHEB buﬀer [20 mM Tris (pH 7.5), 5 mM KCl, 1.5 mM MgCl2, 1 mM
dithiothreitol] and incubated for 30 min at 4 C with rotation followed
by addition of 10 ll of glutathione-Sepharose 4B beads (Amersham
Bioscience) and incubation at 4 C for 1 h. The beads were pelleted,
washed 3 times in NETN buﬀer [50 mM Tris (pH 7.5), 150 mM NaCl,
0.5 mM EDTA, and 0.5% NP-40], pelleted again, resuspended in
Laemmli sample buﬀer, and analyzed by SDS–PAGE. Proteins
were transferred to PVDFmembrane and visualized using streptavidin-
labeled horseradish peroxidase and ECL reagent (Amersham
Bioscience).3. Results
3.1. Eﬀect of propofol on HIF-1a and HIF-1b protein
expression and its dependency on O2 concentration
To examine the eﬀect of propofol on HIF-1 activity, Hep3B
cells were treated with or without propofol under non-hypoxic
(20% O2) or hypoxic (1% O2) conditions. HIF-1a protein levels
were low under non-hypoxic conditions, and increased mark-
edly in response to hypoxic conditions (Fig. 1A, upper; lanes 1
and 3). 100 lM propofol inhibited the expression of HIF-1a
under non-hypoxic conditions (lanes 1 and 2). In contrast,
hypoxic induction of HIF-1a protein accumulation was not
suppressed by propofol treatment (lanes 3 and 4). Expression
of HIF-1b was not aﬀected by exposure to hypoxia or propofol
(Fig. 1A, lower). The suppressive eﬀect of propofol on the
expression of HIF-1a under non-hypoxic conditions was de-
pendent on concentrations of propofol P 10 lM (Fig. 1B).
Fig. 3. Eﬀect of propofol on the expression of HIF-1-dependent genes
or related genes. (A) Hep3B cells were exposed to 20% or 1% O2 with
or without 100 lM propofol for 24 h and total RNA was isolated.
Expressions mRNA of LDHA, VEGF, PHD-1-3, FIH-1 and HIF-1a
and 18s were analyzed by RT-PCR using speciﬁc primer pairs.
Quantiﬁcation of ampliﬁed mRNA was done by densitometry assisted
by the image analysis software NIH Image (version 1.62) and indicated
as fold induction to each lane 1. (B) Hep3B were transfected with p2.1
reporter. After 6 h incubation, cells were treated with 20 or 100 lM
propofol under 20% (upper) or 1% O2 (lower) for 18 h and harvested
for luciferase assays. The relative luciferase activity (RLA) was based
on the value of non-hypoxic untreated cells. Results were shown rep-
resent meanS.D. of six independent transfections.
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addition (Fig. 1C).
To investigate if the eﬀect of propofol on HIF-1a protein
accumulation is O2-concentration-dependent or not, Hep3B
cells were exposed to 20%, 5%, or 1% O2 for 4 h with or
without 100 lM of propofol. Induction of HIF-1a protein was
inversely correlated with O2 concentration (Fig. 1D, lanes 1, 3,
and 5). Propofol suppressed HIF-1a protein expression in cells
exposed to 20% or 5% O2 (lanes 2 and 4). In contrast, induc-
tion of HIF-1a protein expression at 1% O2 was not signiﬁ-
cantly suppressed by propofol (lane 6).
3.2. Eﬀects of propofol are not cell-speciﬁc
In addition to in Hep3B cells, propofol suppressed the basal
expression of HIF-1a under normoxic conditions in HEK293
cells (Fig. 2A) and HUVECs (Fig. 2B). HIF-1a accumulation
in cells exposed to 1% O2 was not aﬀected in either HEK293
cells or HUVECs.
3.3. Eﬀect of propofol on HIF-1-dependent gene expression
We investigated the eﬀect of propofol on hypoxia-induced
HIF-1-mediated gene expression. The mRNA expression of
genes was assayed using RT-PCR technique. Propofol sup-
pressed the basal expression of mRNA of LDHA, VEGF,
PHD-3 and FIH-1 under non-hypoxic conditions but not un-
der hypoxic conditions, data which are consistent with the
eﬀect of propofol on HIF-1a protein levels (Fig. 3A). Ex-
pression of PHD-1, PHD-2 and HIF-1a mRNA was not af-
fected by either propofol or hypoxia.
The eﬀect of propofol on HIF-1 activity was also investi-
gated in Hep3B cells using an HRE-luciferase reporter con-
struct. Twenty lM of propofol inhibited the hypoxia-induced
HRE-dependent gene expression only marginally whereas 100
lM of propofol inhibited reporter gene expression by about
35% (Fig. 3B).
3.4. Eﬀect of antioxidants on HIF-1a protein expression
Propofol is a phenol and reported to serve as an antioxidant
[13]. To approach the molecular mechanism of propofol
action, we decided to use other well-known antioxidants
(Fig. 4A). HIF-1a expression was suppressed by propofol (laneFig. 2. The eﬀects of propofol on HIF-1 in HEK293 cells and
HUVECs. HEK293 cells (A) and HUVECs (B) were exposed to 20%
or 1% O2 with or without 100 lM propofol for 4 h and harvested for
immunoblot assays using anti-HIF-1a and -HIF-1b Abs.
Fig. 4. Comparison of propofol and other antioxidants. (A) Hep3B
cells were exposed to propofol (100 lM), ascorbate (100 lM), a-to-
copherol (a-toco.) (10 lM), DTT (100 lM), and NAC (10 mM) for 4 h
under 20% O2 conditions. (B) Hep3B cells were exposed to 2,6-Di-
isopropylphenol (propofol) and 2,4-Diisopropylphenol for 4 h under
20% O2 conditions. Lysates were prepared and were subjected to
Western blot using anti-HIF-1a Ab.2). In contrast, neither a-tocopherol (lane 4), DTT (lane 5), nor
NAC (lane 6) suppressed the expression of HIF-1a. In con-
trast, ascorbate, which is a potent activator of the HIF-1a
prolyl hydroxylases, suppressed the expression (lane 3). 2,4-
Diisopropylphenol is an isomer of propofol (2,6-diisopropyl-
phenol) and does not have a potency to bind to GABA
receptor of neuronal cells. Both 2,6-diisopropylphenol (pro-
pofol) (Fig. 4B, lane 2) and 2,4-diisopropylphenol (lane 3)
suppress the expression of HIF-1a under 20% conditions,
suggesting that the eﬀect of propofol is not explained via
GABA receptor binding.
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HIF-1a
HIF-1a levels are determined by the balance between syn-
thesis and degradation [5]. The O2-dependent degradation of
HIF-1a is governed by the activity of prolyl hydroxylases of
HIF-1a and subsequent ubiquitination of HIF-1a by a ubiq-
uitin ligation system that includes VHL as an essential com-
ponent [5]. Interaction between HIF-1a and VHL is governed
by hydroxylation status of HIF-1a. We investigated the eﬀects
of propofol on the prolyl hydroxylation of HIF-1a using an in
vitro assay system. Propofol did not aﬀect the prolyl hydrox-
ylation of HIF-1a (Fig. 5A, lane 3). In contrast, DFX inhibited
hydroxylation (lane 4). We next examined the eﬀect of pro-
pofol on HIF-1a accumulation induced by the iron chelatorFig. 5. Eﬀect of propofol on the degradation or synthesis of HIF-1a.
(A) GST-HIF-1a (429–608) fusion protein was incubated with in vitro
translated VHL in the presence of PBS or cell lysates untreated or
treated with the indicated reagents (lanes 1–4). Glutathione-Sepharose
beads were used to capture GST-HIF-1a (429–608) and the presence of
bound VHL was determined by PAGE. One-ﬁfth of the input VHL
protein was also analyzed (lane 5). (B) Hep3B cells were treated with
100 lM CHX, ascorbate, propofol, and 50 lM MG132 under coex-
istence with 100 lM DFX for 4 h in 20% O2. (C) Hep3B cells were
treated with 100 lM CHX, 100 lM ascorbate, 20 lM propofol, or 100
lM propofol coexistent with or without 50 lM MG132. (D) Hep3B
cells were treated with 100 lM propofol or 100 lM CHX. Lysate were
analyzed by Western blot using anti-HIF-1a and ERK3 Abs.DFX. Propofol decreased the expression of HIF-1a in cells
exposed to 100 lm DFX (Fig. 5B, lane 5). Exposure of cells to
CHX (lane 3) or ascorbate (lane 4) had inhibitory eﬀect on
HIF-1a levels, although the mechanism of the inhibition dif-
fers. CHX decreased HIF-1a protein by inhibition of protein
translation whereas ascorbate, which is a cofactor for the
prolyl hydroxylases, stimulated HIF-1a protein degradation.
Exposure of cells to MG132, a proteasome inhibitor, causes
cells to accumulate HIF-1a protein (lane 6). Hep3B cells were
treated with propofol or ascorbate in the presence of MG132
(Fig. 5C). Ascorbate did not suppress the accumulation of
HIF-1a under MG132 (lane 8). Propofol (lanes 9 and 10) as
well as CHX (lane 7) inhibited the accumulation of HIF-1a
induced by MG132 treatment in a dose dependent manner.
Finally the speciﬁcity of propofol as an inhibitor of protein
synthesis was investigated (Fig. 5D). ERK3 is a protein with
rapid turnover and mainly degradated by ubiquitin–protea-
some system [14]. Notably, propofol selectively suppresses
HIF-1a protein synthesis (lane 2). In contrast, CHX, which is a
general translational inhibitor, suppresses both HIF-1a and
ERK3 synthesis (lane 3).4. Discussion
In this report we have demonstrated a reversible inhibitory
eﬀect of propofol on HIF-1 activity. The suppressive eﬀect of
propofol on HIF-1a protein expression was signiﬁcant at 20%
and 5% O2 but not at 1% O2. Propofol suppressed HIF-1 ac-
tivity under 20% O2 assayed by RT-PCR (Fig. 3A) and an
HRE-luciferase reporter construct (Fig. 3B).
Several reports indicate that propofol has antioxidant ac-
tivity related to its phenolic group [13,15] and intracellular
redox balance is known to aﬀect HIF-1 activity [16]. But our
results of Fig. 4A, especially the result from a-tocopherol,
strongly suggested that the antioxidant activity of propofol
does not explain the suppressive eﬀect.
O2-dependent regulation of HIF-1 activity occurs via mul-
tiple mechanisms including eﬀects on HIF-1a expression, in-
tracellular localization of the HIF-1a:HIF-1b complex, and
transcriptional activity of HIF-1a. Among them, regulations
of HIF-1a expression level and transcriptional activity are the
most crucial steps. The expression of HIF-1a is determined by
a balance between degradation and synthesis. In this study,
we demonstrate that propofol does not inhibit the interaction
between HIF-1a and VHL and that propofol does not sup-
press hypoxia-induced HIF-1a accumulation signiﬁcantly.
The data from Fig. 5C indicate that propofol suppress the
accumulation of HIF-1a as well as CHX, a protein transla-
tion inhibitor, even after inhibition of proteasome system.
Taken together with data that propofol does not inﬂuence
HIF-1a mRNA expression (Fig. 3A), our results indicate that
propofol does not aﬀect the HIF-1a-hydroxylase activity but
suppresses the translation of HIF-1a mRNA into protein.
Although the details of molecular process of HIF-1a synthesis
are still to be elucidated, mitogen activation protein kinase
(MAPK) and PI3 kinase activity play signiﬁcant roles in de-
termining the translational rate of HIF-1a from mRNA [8].
In fact, propofol is reported to suppress MAPK activity [17].
The inhibitory eﬀect of propofol on HIF-1a synthesis is
speciﬁc because propofol did not aﬀect the protein expression
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teasome system (Fig. 5D). In contrast to results shown at the
protein level, propofol seems to have an eﬀect on HIF-1 ac-
tivity judged from luciferase assay (Fig. 3C) in normoxia and
in hypoxia. We have experimental data that propofol sup-
presses the GAL4-HIF-1a-transactivation domain-dependent
gene expression under both normoxia and hypoxia (data not
shown). The suppression of MAPK, which plays an critical
role in regulation of the HIF-1a-transactivity, may contribute
to the inhibition. The evidence at least partially explain
the discrepancy between the protein expression and the
activation.
A notable ﬁnding in this study is that the eﬀect of pro-
pofol on HIF-1a expression is dependent on O2 tension. As
shown in Fig. 1D, under 20% and 5% O2 conditions, the
inhibitory eﬀect is prominent but under 1% O2 condition,
the eﬀect is not barely observed. Lang et al. [18] reported the
presence of IRES in the HIF-1a 50UTR promoter region.
They also indicated that IRES activity is not aﬀected by
hypoxic conditions that caused a reduction in cap-dependent
translation, and IRES activity was less aﬀected by serum-
starvation than was cap-dependent translation. Propofol may
aﬀect IRES- and cap-dependent translation diﬀerentially.
Propofol is reported to inhibit lactate production [19,20]. On
the other hand, a report describes that propofol suppresses
macrophage functions and ATP synthesis [21]. In fact, we also
observed that propofol decreased cellular lactate and increased
cellular pyruvate (manuscript in preparation), and furthermore
decreased LDHA mRNA expression (Fig. 3A). The conver-
sion from pyruvate to lactate is an important reaction for
supplying NADþ to promote glycolytic pathway. Propofol
may decrease energy supply in the cells by the suppression of
glycolytic pathway, secondary to decreased HIF-1 activity.
Inhibitory eﬀects on HIF-1a protein synthesis and on HIF-1
target gene expression were observed at a clinically relevant
dose of propofol.
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